Vumerity
Phase 1Small molecule
Vumerity is one of 31 small molecule programs targeting Peripheral Artery Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Peripheral Artery Disease
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Benicar
NovartisApproved
Kuvan
BioMarin PharmaceuticalApproved
Xarelto
WWim Janssens
Approved
Glucophage
EMD SeronoApproved
Zocor
OOrganon and Co
Approved
Brilinta
AstraZenecaPhase 3
Acetylsalicylic Acid
BayerApproved
Bayer Aspirin
BayerPhase 3
Colcrys
Alnylam PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vumerity. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Nebraska